- Learn the basics
- Find stocks
- Understand a stock
Corvus Pharmaceuticals, Inc.
CRVS United States NASDAQCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
In short
Loading the key numbers…
What the sector means for this company
These sentences describe the numbers; they are not a recommendation. This content is not investment advice.
Price chart: each candle shows one day's opening, highest, lowest and closing price. The projection line is our model's estimate - a model, not a promise.
Price chart
Key statistics: the most used ratios in one place. Tap the icon next to a name for a short explanation. Compare them with similar companies, not with the whole market.
Financial statements: the income statement shows sales and profit, the balance sheet what the company owns and owes, and the cash flow statement the money that actually came in and went out. How to read them.
Company policy and leadership: an AI-assisted assessment of how the company sells, executes, uses its resources and treats people, production and service. Read it as a starting point for your own research.
News: the latest articles about the company, grouped by day. Each has ratings for the outlet's stance towards the company and how factual it is. What the ratings mean.